Repros expects November verdict on hypogonadism drug
This article was originally published in Scrip
Executive Summary
If all goes well, Repros Therapeutics could have a decision by 30 November – the date the FDA has set under the Prescription Drug User Fee Act – on the company’s new drug application (NDA) for its enclomiphene citrate product candidate, formerly known as Androxal.